Ignite Creation Date:
2024-05-06 @ 3:21 AM
Last Modification Date:
2024-10-26 @ 11:32 AM
Study NCT ID:
NCT02265068
Status:
COMPLETED
Last Update Posted:
2018-06-14
First Post:
2014-10-09
Brief Title:
Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes
Sponsor:
IHF GmbH - Institut für Herzinfarktforschung
Organization:
IHF GmbH - Institut für Herzinfarktforschung
Study Overview
Official Title:
Real-TICA Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes Evaluation of Antiplatelet Therapy After 12 Months in Patients Undergoing PCI and Treated With Ticagrelor During the Acute Phase of an ACS
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Real-TICA
Brief Summary:
Documentation of long-term data regarding ticagrelor use and evaluation of reasons for discontinuation of ticagrelor in patients with ACS
Detailed Description:
REAL-TICA is a retrospective non-interventional study to assess the long-term use of ticagrelor in patients with ACS and to evaluate the reasons for discontinuation of ticagrelor
For this purpose selected sites from the ALKK-PCI registry and the respective patients will be identified The sites eligibility for this study includes the frequent use of ticagrelor during the acute phase of ACS Eligible patients are characterised by the diagnosis of ACS and the use of ticagrelor during PCI
The eligible sites will be contacted by IHF and asked to contact their eligible patients by letter to obtain informed consent of the patients for the planned 12M follow-up by IHF A detailed questionnaire on events within the last 12 months current symptoms current medication and the use of ticagrelor will be added to the patients letters Patients then are asked to return their responses on consent to participate in the study as well as the filled in questionnaire to IHF Alternatively patients may choose to receive a telephone call by IHF to answer the detailed questionnaire in person In case of essential information missing IHF will contact the primary care physician of the patient directly to obtain information about clinical events and medications
For this purpose selected sites from the ALKK-PCI registry and the respective patients will be identified The sites eligibility for this study includes the frequent use of ticagrelor during the acute phase of ACS Eligible patients are characterised by the diagnosis of ACS and the use of ticagrelor during PCI
The eligible sites will be contacted by IHF and asked to contact their eligible patients by letter to obtain informed consent of the patients for the planned 12M follow-up by IHF A detailed questionnaire on events within the last 12 months current symptoms current medication and the use of ticagrelor will be added to the patients letters Patients then are asked to return their responses on consent to participate in the study as well as the filled in questionnaire to IHF Alternatively patients may choose to receive a telephone call by IHF to answer the detailed questionnaire in person In case of essential information missing IHF will contact the primary care physician of the patient directly to obtain information about clinical events and medications
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None